TXR-612

TXR-612 is a preclinical **small molecule** drug candidate being developed by Aria Pharmaceuticals for **nonalcoholic steatohepatitis**. Publicly available company materials describe it as one of two lead compounds identified through Aria's computational discovery platform and characterize it as having a **novel mechanism of action**, but the specific molecular target and pharmacology have not been publicly disclosed. In preclinical reports, TXR-612 showed activity in primary human hepatic stellate cells by modulating fibrosis-associated gene and protein expression, and it demonstrated efficacy and tolerability in the STAM mouse model with reductions in liver weight, steatosis, ballooning, fibrillar collagen deposition, and NAFLD activity score. No approved brand name, clinical-stage development details, or explicit route and formulation information were identified from the available public sources.